Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, is enhancing its footprint in the United States with a new office in Cambridge, Massachusetts. This strategic expansion places IAG’s operations and business development teams in close proximity to leading biotechnology and pharmaceutical companies in the Boston area, fostering stronger partnerships and providing vital local support for regional clinical trials.
The Cambridge office is a critical step in IAG’s mission to advance its work across various therapeutic fields, such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. The location is expected to facilitate collaboration with sponsors and contract research organizations involved in Phase I–III clinical trials and projects that require intensive imaging development.
In addition to strengthening industry connections, IAG plans to generate local job opportunities, with recruitment efforts targeting positions in clinical imaging operations, data science, regulatory support, and business development over the next 12 to 24 months. The office will bolster IAG’s comprehensive imaging services, which include clinical trial design consultation, optimized imaging protocols, centralized image analysis, and regulatory-compliant data delivery.
By establishing a presence in the Boston life-sciences ecosystem, IAG aims to enhance its collaboration with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers. This move aligns with IAG’s global operations strategy, which spans North America, Europe, and the Asia-Pacific region, offering standardized imaging protocols and consistent imaging analysis for international trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO), supporting pharmaceutical, biotechnology, and medical technology companies with imaging-based clinical trial endpoints. Their DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, solidifying IAG’s role in advancing clinical research across multiple disease indications.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.